Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Effects of sitagliptin on counterregulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double blind placebo-controlled cross-over study.

Schopman JE, Hoekstra JB, Frier BM, Ackermans MT, de Sonnaville JJ, Stades AM, Zwertbroek R, Hartmann B, Holst JJ, Knop FK, Holleman F.

Diabetes Obes Metab. 2015 Feb 19. doi: 10.1111/dom.12453. [Epub ahead of print]

PMID:
25694217
[PubMed - as supplied by publisher]
2.

Patients with psoriasis are insulin resistant.

Gyldenløve M, Storgaard H, Holst JJ, Vilsbøll T, Knop FK, Skov L.

J Am Acad Dermatol. 2015 Feb 1. pii: S0190-9622(15)00007-9. doi: 10.1016/j.jaad.2015.01.004. [Epub ahead of print]

PMID:
25653028
[PubMed - as supplied by publisher]
3.

A 25-year-old woman with type 2 diabetes and liver disease.

Junker AE, Gluud LL, Pedersen J, Langhoff JL, Holst JJ, Knop FK, Vilsbøll T.

Case Rep Gastroenterol. 2014 Dec 12;8(3):398-403. doi: 10.1159/000369968. eCollection 2014 Sep-Dec.

PMID:
25606030
[PubMed]
Free PMC Article
4.
5.

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.

Chalmer T, Almdal TP, Vilsbøll T, Knop FK.

Expert Opin Drug Saf. 2015 Jan;14(1):171-80. doi: 10.1517/14740338.2015.975205. Epub 2014 Nov 3.

PMID:
25363438
[PubMed - in process]
6.

Glucagon and type 2 diabetes: the return of the alpha cell.

Lund A, Bagger JI, Christensen M, Knop FK, Vilsbøll T.

Curr Diab Rep. 2014 Dec;14(12):555. doi: 10.1007/s11892-014-0555-4.

PMID:
25344790
[PubMed - in process]
7.

Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients.

Jørgensen MB, Idorn T, Knop FK, Holst JJ, Hornum M, Feldt-Rasmussen B.

Nephrol Dial Transplant. 2015 Mar;30(3):513-20. doi: 10.1093/ndt/gfu327. Epub 2014 Oct 15.

PMID:
25319937
[PubMed - in process]
8.

Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients.

Ebdrup BH, Knop FK, Madsen A, Mortensen HB, Søgaard B, Holst JJ, Szecsi PB, Lublin H.

J Clin Psychiatry. 2014 Sep;75(9):e899-905. doi: 10.4088/JCP.13m08820.

PMID:
25295432
[PubMed - indexed for MEDLINE]
Free Article
9.

[Duodenal-jejunal bypass sleeve - a potential alternative to bariatric surgery?]

Rohde U, Gylvin S, Vilmann P, Friis SU, Langholz E, Vilsbøll T, Knop FK.

Ugeskr Laeger. 2014 Sep 8;176(37). pii: V01140053. Danish.

PMID:
25294038
[PubMed - as supplied by publisher]
10.

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes.

Sonne DP, Lund A, Faber J, Holst JJ, Vilsbøll T, Knop FK.

Endocr Connect. 2014 Dec;3(4):193-9. doi: 10.1530/EC-14-0088. Epub 2014 Oct 2.

PMID:
25277744
[PubMed]
Free PMC Article
11.
12.

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.

Nissen A, Christensen M, Knop FK, Vilsbøll T, Holst JJ, Hartmann B.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2325-9. doi: 10.1210/jc.2014-2547. Epub 2014 Aug 21.

PMID:
25144635
[PubMed - indexed for MEDLINE]
13.

Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients - a randomized placebo-controlled trial.

Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629. Epub 2014 Aug 20.

PMID:
25139195
[PubMed - in process]
14.

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.

Christensen M, Miossec P, Larsen BD, Werner U, Knop FK.

Expert Opin Drug Discov. 2014 Oct;9(10):1223-51. doi: 10.1517/17460441.2014.942638. Epub 2014 Aug 14.

PMID:
25119443
[PubMed - in process]
15.

Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.

Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, Purrello F, van Hall G, Holst JJ, Vilsbøll T, Knop FK.

Diabetes. 2015 Jan;64(1):72-8. doi: 10.2337/db14-0440. Epub 2014 Jul 22.

PMID:
25053587
[PubMed - in process]
16.

Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.

Brønden A, Hansen M, Sonne DP, Rohde U, Vilsbøll T, Knop FK.

Diabetes Obes Metab. 2015 Feb;17(2):116-20. doi: 10.1111/dom.12355. Epub 2014 Jul 31.

PMID:
25041567
[PubMed - in process]
17.

Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies.

Bak MJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK, Vilsbøll T, Jørgensen NB, Hartmann B, Deacon CF, Dragsted LO, Holst JJ.

Diabetes Obes Metab. 2014 Nov;16(11):1155-64. doi: 10.1111/dom.12352. Epub 2014 Jul 22.

PMID:
25041349
[PubMed - in process]
18.

The use of double-balloon enteroscopy in retrieving mucosal biopsies from the entire human gastrointestinal tract.

Rhee NA, Vilmann P, Hassan H, Hendel JW, Holst JJ, Vilsbøll T, Knop FK.

Scand J Gastroenterol. 2014 Sep;49(9):1143-9. doi: 10.3109/00365521.2014.934912. Epub 2014 Jul 7.

PMID:
24998781
[PubMed - in process]
19.

Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.

Sonne DP, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK.

Eur J Endocrinol. 2014 Oct;171(4):407-19. doi: 10.1530/EJE-14-0309. Epub 2014 Jul 1.

PMID:
24986531
[PubMed - indexed for MEDLINE]
20.

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.

Rhee NA, Østoft SH, Holst JJ, Deacon CF, Vilsbøll T, Knop FK.

Eur J Endocrinol. 2014 Sep;171(3):353-62. doi: 10.1530/EJE-14-0314. Epub 2014 Jun 16.

PMID:
24935932
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk